Authorized purpose: Worklist triage and notification for suspected incidental pulmonary embolism on contrast-enhanced CT acquired for another indication; not a diagnostic device
Clinical role
Standalone triage application operating in parallel with standard of care; all studies appear in the worklist, flagged series receive notification and passive marking, and the original images remain the basis for review
Images and patients
CT/CTA · Lung and pulmonary arterial segments containing incidental pulmonary embolism; subsegmental arteries are out of scope
Key limitation
Keep in mind: Not designed to detect PE in subsegmental arteries; preview images are informational and not diagnostic; results are not for standalone diagnosis and notified clinicians must review the full study using standard of care; the input is CT for another indication rather than a dedicated CTPA protocol
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Worklist triage and notification for suspected incidental pulmonary embolism on contrast-enhanced CT acquired for another indication; not a diagnostic device
Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Lung and pulmonary arterial segments containing incidental pulmonary embolism; subsegmental arteries are out of scope Input: DICOM contrast-enhanced CT scans, not dedicated CTPA, including at least part of the lung; intended for adults and transitional adolescents aged 18-21 treated as adults
Who uses it?Intended users: Hospital networks and trained radiologists
What does the software produce?Output: Passive worklist icon and active notification for suspected incidental PE, with a compressed grayscale unannotated preview marked not for diagnostic use; results files are transferred for PACS/workstation prioritization and the original image is not altered
What is its most important limitation?Key limitation: Not designed to detect PE in subsegmental arteries; preview images are informational and not diagnostic; results are not for standalone diagnosis and notified clinicians must review the full study using standard of care; the input is CT for another indication rather than a dedicated CTPA protocol
Clinical takeaway. Clinical role: Worklist triage and notification for suspected incidental pulmonary embolism on contrast-enhanced CT acquired for another indication; not a diagnostic device
Evidence takeaway. Evidence from the reviewed source record: Retrospective multicenter, multinational, blinded standalone study of 381 cases: 181 positive and 200 negative, with ground truth by consensus of three US-board-certified expert radiologists. Global sensitivity was 87.8% (95% CI 82.2%-92.2%) and specificity 92.0% (87.3%-95.4%) against an 80% performance goal. Sensitivity by overlapping lesion-location groups was main 96.3%, interlobar 94.5%, lobar 92.9%, and segmental 88.3%. Mean time-to-notification was 1.5 minutes for all cases and 1.5 minutes for 159 true-positive cases
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Worklist triage and notification for suspected incidental pulmonary embolism on contrast-enhanced CT acquired for another indication; not a diagnostic device
Standalone triage application operating in parallel with standard of care; all studies appear in the worklist, flagged series receive notification and passive marking, and the original images remain the basis for review
DICOM contrast-enhanced CT scans, not dedicated CTPA, including at least part of the lung; intended for adults and transitional adolescents aged 18-21 treated as adults
Passive worklist icon and active notification for suspected incidental PE, with a compressed grayscale unannotated preview marked not for diagnostic use; results files are transferred for PACS/workstation prioritization and the original image is not altered
Not designed to detect PE in subsegmental arteries; preview images are informational and not diagnostic; results are not for standalone diagnosis and notified clinicians must review the full study using standard of care; the input is CT for another indication rather than a dedicated CTPA protocol
Retrospective multicenter, multinational, blinded standalone study of 381 cases: 181 positive and 200 negative, with ground truth by consensus of three US-board-certified expert radiologists. Global sensitivity was 87.8% (95% CI 82.2%-92.2%) and specificity 92.0% (87.3%-95.4%) against an 80% performance goal. Sensitivity by overlapping lesion-location groups was main 96.3%, interlobar 94.5%, lobar 92.9%, and segmental 88.3%. Mean time-to-notification was 1.5 minutes for all cases and 1.5 minutes for 159 true-positive cases
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
Retrospective multicenter, multinational, blinded standalone study of 381 cases: 181 positive and 200 negative, with ground truth by consensus of three US-board-certified expert radiologists. Global sensitivity was 87.8% (95% CI 82.2%-92.2%) and specificity 92.0% (87.3%-95.4%) against an 80% performance goal. Sensitivity by overlapping lesion-location groups was main 96.3%, interlobar 94.5%, lobar 92.9%, and segmental 88.3%. Mean time-to-notification was 1.5 minutes for all cases and 1.5 minutes for 159 true-positive cases
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
CINA-iPE regulatory performance study summary
DesignStand-Alone Performance
PopulationAdult
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K233968
Samplen=381
IndependenceIndependence not established
K233968
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K233968. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: DICOM contrast-enhanced CT scans, not dedicated CTPA, including at least part of the lung; intended for adults and transitional adolescents aged 18-21 treated as adults
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: CINA-iPE can run with the CINA Platform cleared under K200855 or another medical image communications device. DICOM services communicate with CT modalities, routers, PACS, and the Worklist Application; exact local interface versions are not established
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes CINA-iPE running on a standard off-the-shelf server/workstation, with an Image Processing Application that can be integrated, deployed, and used with the CINA Platform (K200855) or other medical image communications devices. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "CINA-iPE runs on a standard “off the shelf” server/workstation and consists of an Image Processing Application, which can be integrated, deployed, and used with the CINA Platform (cleared under K200855) or other medical image communications devices." … "The CINA platform is an example of medical image communications platform for integrating and deploying the CINA-iPE image processing application.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: Passive worklist icon and active notification for suspected incidental PE, with a compressed grayscale unannotated preview marked not for diagnostic use; results files are transferred for PACS/workstation prioritization and the original image is not altered
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Passive worklist icon and active notification for suspected incidental PE, with a compressed grayscale unannotated preview marked not for diagnostic use; results files are transferred for PACS/workstation prioritization and the original image is not altered
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes CINA-iPE running on a standard off-the-shelf server/workstation, with an Image Processing Application that can be integrated, deployed, and used with the CINA Platform (K200855) or other medical image communications devices. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "CINA-iPE runs on a standard “off the shelf” server/workstation and consists of an Image Processing Application, which can be integrated, deployed, and used with the CINA Platform (cleared under K200855) or other medical image communications devices." … "The CINA platform is an example of medical image communications platform for integrating and deploying the CINA-iPE image processing application.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
CINA-iPE can run with the CINA Platform cleared under K200855 or another medical image communications device. DICOM services communicate with CT modalities, routers, PACS, and the Worklist Application; exact local interface versions are not established
Avicenna.AI's cybersecurity page states ISO/IEC 27001 certification by SGS, IEC 81001-5-1, TLS 1.2+ in transit, encryption at rest, role-based access with least privilege, and a HIPAA business associate agreement for US customers. Vendor-wide.
Vendor-wide
Checked 2026-10-25
Vendor statement, not an attestation; exact-release scope is not established.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
24Fields reviewed
10Source classes checked
2Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains 2 PubMed and 0 ClinicalTrials.gov candidate records. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 2 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, vendor documentation, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission
No public price or quote for the exact K233968 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-08 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring: Not verified - checked 2026-09-08 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Authorized purpose: Parallel notification of suspected anterior-circulation large vessel occlusion on acute head CTA for specialist review; notification only, not diagnosis.
Modality
CT/CTA
Anatomy
Brain anterior circulation: internal carotid artery and M1 segment of the middle cerebral artery
Authorized purpose: Rapid CTA 360 analyzes adult head CTA DICOM images to flag suspected large- and medium-vessel occlusion in specified intracranial and vertebral segments and notify trained clinicians for workflow triage; notifications are informational and not diagnostic.
Authorized purpose: AI-assisted acute-care triage and notification of suspected large-vessel occlusion on contrast-enhanced head CTA to prioritize review; not diagnosis.
Modality
CT/CTA
Anatomy
Brain/head vasculature, specifically the ICA, M1, and M2 segments
Authorized purpose: Parallel-workflow triage and notification of suspected incidental pulmonary embolism on contrast-enhanced images that include the lungs.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.